Letrozol Aristo® 2,5 mg

Description

Form of release

• Yellow film-coated tablets, round, biconvex, cross-sectional – white or white core with yellowish tinge.
• Pharmacotherapeutic group
• Antineoplastic agent, estrogen synthesis inhibitor.

Pharmacological properties

Anticancer agent. It is a non-steroidal inhibitor of aromatase, an enzyme involved in the synthesis of oestrogen in postmenopausal women. Aromatase promotes the conversion of androgens synthesised in the adrenal glands (mainly androstendione and testosterone) to estrone and estradiol. Inhibition of aromatase activity is achieved through a cometic binding to the heme subunit of this enzyme, cytochrome P450, leading to a reduction in estrogen biosynthesis in all tissues, including estrogen-dependent tumour tissues.

Indications

Early stages of invasive breast cancer whose cells have receptors for hormones, in postmenopausal women, as complementary treatment.
Early stage invasive breast cancer in postmenopausal women after completion of standard adjuvant treatment with tamoxifen for 5 years as extended adjuvant treatment.
Disseminated hormone-dependent breast cancer in postmenopausal women (first-line therapy).
Disseminated breast cancer with disease recurrence or progression in postmenopausal women (natural or artificially induced) who have received prior anti-estrogen therapy. – Hormone-dependent HER-2 negative breast cancer in postmenopausal women as neoadjuvant therapy when chemotherapy is contraindicated and salvage surgery is not necessary.